We are live on ! Find out more
VRNA

Verona Pharma
VRNA

Delisted

VRNA was delisted on the 6th of October, 2025.

Back to rankings

18 hedge funds and large institutions have $33.6M invested in Verona Pharma in 2020 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

400% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 1

29% more funds holding

Funds holding: 14 → 18 (+4)

17% more capital invested

Capital invested by funds: $28.8M → $33.6M (+$4.8M)

0.16% more ownership

Funds ownership: 6.58% → 6.74% (+0.16%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

Holders
18
Holders Change
+4
Holders Change %
+28.57%
% of All Funds
0.37%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
5
Increased
2
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BBVA
Banco Bilbao Vizcaya Argentaria
Spain
+$278K
2
SB
Samsara BioCapital
California
+$201K
3
WS
Wedbush Securities
California
+$177K
4
DADC
D.A. Davidson & Co
Montana
+$139K
5
Renaissance Technologies
Renaissance Technologies
New York
+$99.1K

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$16K

VRNA Hedge Fund Activity: Q2 2020 in Review

18 of the 4,873 institutional investors tracked by Wall St. Rank reported a position in Verona Pharma (VRNA) for Q2 2020, worth a combined $33.6M — up 17% from $28.8M a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new VRNA positions and 1 closed out — a net gain of 4 holders — while 2 added to existing stakes and 0 trimmed.

The largest buyer was Banco Bilbao Vizcaya Argentaria, opening a new position worth an estimated $278K. The largest seller was UBS Group, exiting entirely with an estimated $16K sold.

  • 18 institutional investors held Verona Pharma (VRNA) as of Q2 2020, up from 14 in Q1 2020.
  • Funds reported $33.6M of Verona Pharma stock for Q2 2020, up 17% quarter-over-quarter.
  • 5 funds opened new Verona Pharma positions in Q2 2020 and 1 closed out, a net change of +4 holders.
  • The largest Verona Pharma buyer in Q2 2020 was Banco Bilbao Vizcaya Argentaria, an estimated $278K added.
  • The largest Verona Pharma seller in Q2 2020 was UBS Group, an estimated $16K sold.

Based on aggregated 13F filings for Q2 2020.